Leukaemia drug wins head-to-head for relapsing MS
The monoclonal antibody is associated with reduced odds of disability progressing, researchers say
Head-to-head comparisons show the monoclonal antibody ofatumumab is associated with a lower relapse rate than teriflunomide in patients with relapsing-remitting multiple sclerosis (MS).
Two studies with identical protocols — the ASCLEPIOS trials I and II initiated and funded by oftumumab manufacturer Novartis — were carried out in 927 and 955 patients, respectively, across 385 centres in 37 countries from 2016-18.
Participants had a mean age of 38 years, two thirds were female, 94% had relapsing-remitting MS
